Department of Radiology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.
Department of Nuclear Medicine and PET Center, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.
Jpn J Radiol. 2016 May;34(5):349-55. doi: 10.1007/s11604-016-0531-9. Epub 2016 Feb 26.
Our aim was to determine whether the maximum standardized uptake value (SUVmax) of the primary lesion demonstrated by [(18)F]-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is associated with the prognosis of maxillary sinus cancer.
The relationships of clinicopathological factors including age, T stage, N stage, histologic type, treatment strategy, and primary tumor SUVmax with progression-free (PFS) and overall (OS) survival were evaluated using the log-rank test and Cox method in 31 patients with maxillary sinus cancer before combined superselective intra-arterial chemotherapy using high-dose cisplatin with concurrent radiotherapy, or radiotherapy alone.
The median duration of follow-up was 55.4 (range 9.7-72.6) months. PFS and OS of patients exhibiting a high SUVmax (≥16 and ≥17, respectively) for the primary tumor were significantly lower than those of patients for whom the primary tumor SUVmax was low (p = 0.0010 and p = 0.033, respectively). Multivariate analyses showed that T stage (p = 0.0049) and primary tumor SUVmax (p = 0.026) were independently prognostic of poorer PFS and that only primary tumor SUVmax (p = 0.049) was independently prognostic of poorer OS.
SUVmax of the primary tumor determined by FDG-PET/CT before treatment could be a good surrogate marker for prognostication of maxillary sinus cancer.
本研究旨在确定经氟-18-脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG-PET/CT）检测的原发肿瘤最大标准化摄取值（SUVmax）是否与上颌窦癌的预后相关。
对 31 例接受高剂量顺铂联合超选择性动脉内化疗及同期放化疗或单纯放疗的上颌窦癌患者，采用 log-rank 检验和 Cox 方法，评估包括年龄、T 分期、N 分期、组织学类型、治疗策略和原发肿瘤 SUVmax 在内的临床病理因素与无进展生存（PFS）和总生存（OS）的关系。
中位随访时间为 55.4 个月（范围 9.7-72.6 个月）。原发肿瘤 SUVmax 较高（≥16 和≥17）的患者 PFS 和 OS 显著低于原发肿瘤 SUVmax 较低的患者（p=0.0010 和 p=0.033）。多因素分析显示，T 分期（p=0.0049）和原发肿瘤 SUVmax（p=0.026）是 PFS 的独立预后因素，仅原发肿瘤 SUVmax（p=0.049）是 OS 的独立预后因素。
治疗前 FDG-PET/CT 检测的原发肿瘤 SUVmax 可作为上颌窦癌预后的良好替代标志物。
